Congenital CYtoMEgalovirus Infection in VIEtnam (CYMEVIE)

Launched by HANOI OBSTETRICS AND GYNECOLOGY HOSPITAL · Mar 28, 2021

Keywords

ClinConnect Summary

The CYMEVIE trial is studying congenital cytomegalovirus (CMV) infection in newborns in Vietnam. CMV is a common virus that can sometimes lead to health problems in babies if they are infected before birth. The goal of this study is to find out how many babies are born with this infection and to track their health for the first two years of life. Researchers will also look at how the virus behaves in pregnant women during their first trimester to understand its potential impact on the baby.

To participate in this trial, women must be Vietnamese and in their first trimester of pregnancy, and they need to give their consent to be part of the study. Unfortunately, women under 18, those who have had miscarriages or stillbirths, or those who deliver prematurely (before 34 weeks of pregnancy) cannot join. Participants can expect to receive regular check-ups and follow-ups to monitor their health and the health of their babies. This study aims to provide valuable insights that could help improve care for pregnant women and newborns in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Vietnamese pregnant women in the first trimester of pregnancy and at delivery and subsequent live neonates at birth.
• • Informed consent
• Exclusion Criteria:
• • Women under 18 years old.
• • Miscarriages
• • Stillbirths
• • Premature delivery before 34th gestational week
• • Loss to follow-up maternal monitoring.
• • Participation in another interventional study that influences management of labour at delivery or perinatal morbidity or mortality.